Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Provided By PR Newswire
Last update: Nov 7, 2024
– Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned –
Read more at prnewswire.com
